Exercise Pre-screening for Cancer Clients

Foundations of Exercise Pre-Screening in Oncology

• Clinical Imperative for Pre-Screening:

  • Exercise pre-screening is an indispensable clinical prerequisite designed to safeguard client health, minimize the risk of exercise-induced adverse events, and establish an individualized, evidence-based exercise prescription.
  • An adverse event refers specifically to an unexpected occurrence arising as a consequence of an exercise session that leads to ill health, physical harm, acute medical complication, or death.
  • At present, no single validated pre-exercise screening tool exists specifically tailored to the unique physiological complexities of cancer populations.
  • Exercise professionals, such as Accredited Exercise Physiologists (AEPs), must rely on thorough evaluations of absolute and relative contraindications, established population screening algorithms, and rigorous clinical judgment to evaluate client safety before commencing or progressing an exercise program.

• Organizational Guidelines and Core Focus Areas:

  • Both the Clinical Oncology Society of Australia (COSA) and the Cancer Council endorse a structured pre-screening process for individuals diagnosed with cancer.
  • The screening process must prioritize three essential clinical domains:
    • Disease-Specific Risks: Characterization of cancer type, anatomical site, histological grade, and clinical stage (including primary disease versus metastatic spread).
    • Treatment History and Toxicities: Chronological review of past, current, and planned antineoplastic treatments, including cumulative exposures and associated acute, chronic, or late-onset side effects.
    • Comorbidities and Current Symptoms: Co-existing chronic pathologies, acute physical symptoms, organ-specific functional impairments, and general clinical presentation.
  • Whenever clinical ambiguity, unrecognized red flags, or complex systemic symptoms arise, exercise professionals must seek immediate medical advice and actively collaborate with the client's oncology and primary healthcare teams.

Adult Pre-Exercise Screening System (APSS) Framework

• Utility of the APSS in Oncology:

  • The Adult Pre-Exercise Screening System (APSS)—developed collaboratively by Exercise & Sports Science Australia (ESSA), Fitness Australia, and Sports Medicine Australia (SMA)—provides a standardized, evidence-informed foundation for initial health risk identification.
  • The APSS serves to:
    • Identify diagnosed medical conditions and unstable pathologies.
    • Quantify baseline physical activity levels and sedentary patterns.
    • Flag overt signs, symptoms, and epidemiological risk factors warranting clinical referral or supervised exercise prescription.

• Identification of Cancer Status within APSS:

  • Active Cancer or Current Treatment: Actively flagged through Stage 1 (Question 6: "Do you have any other conditions that may require special consideration for you to exercise?") and Stage 2 (Question 15), mandating secondary clinical review or medical clearance prior to commencing vigorous exercise.
  • Disease-Free and Post-Treatment Survivors: Frequently uncaptured by standard APSS screening items, as individuals completing therapy years prior may not perceive their history as an active health condition. Clinicians must specifically inquire about prior cancer diagnoses, surgical interventions, and cardiotoxic exposure during the past medical history interview.

• Structure of APSS Stage 1 (Compulsory Screening):
  • Core Question 1: Medical diagnosis of a heart condition or history of stroke.
  • Core Question 2: Unexplained pain or discomfort in the chest occurring at rest or during physical activity/exercise.
  • Core Question 3: Episodes of faintness, dizziness, or loss of balance during physical activity/exercise.
  • Core Question 4: Asthma attack requiring immediate medical attention within the past $12\,\text{months}$.
  • Core Question 5: In individuals with type 1 or type 2 diabetes, difficulty controlling blood glucose levels within the preceding $3\,\text{months}$.
  • Core Question 6: Presence of any other medical conditions that may require special consideration prior to exercising.
  • Action Triage for Questions 1–6: An affirmative response ("YES") to any single question requires guidance and clearance from an appropriate allied health professional or medical practitioner prior to undertaking exercise.
  • Physical Activity Volume Calculation (Question 7):
    • Clients ticking "NO" to all six questions quantify their current habitual physical activity across light, moderate, and vigorous/high intensities.
    • $\text{Total Weighted Physical Activity Minutes} = (\text{Minutes of Light} + \text{Moderate}) + (2 \times \text{Minutes of Vigorous/High})$
    • Volume Thresholds:
      • If total weighted volume is $< 150\,\text{min}\,\text{week}^{-1}$: Light- to moderate-intensity exercise is recommended, with gradual, progressive increases in volume and intensity.
      • If total weighted volume is $\ge 150\,\text{min}\,\text{week}^{-1}$: Client may continue current exercise volume and intensity, consulting an exercise professional for structured progression across volume, intensity, duration, and modality.

Clinical Indications for Medical Clearance and Treatment Timing

• ACSM Guidelines on Medical Clearance:

  • Malignancy and multimodal treatments produce pronounced adverse effects across multiple physiological systems, including cardiovascular, pulmonary, immune, musculoskeletal, and neurological functions.
  • Despite these impairments, the American College of Sports Medicine (ACSM) 2019 guidelines (Campbell et al., 2019) emphasize that formal medical clearance is not routinely required for individuals with a history of cancer before initiating an exercise program.

• Rationale for Reducing Universal Clearance Requirements:

  • 2015 ACSM Model Realignment: The paradigm shifted away from broad, non-specific risk stratification toward targeted identification of individuals with known active disease or overt signs/symptoms of cardiovascular, metabolic, or renal dysfunction.
  • Safety of Moderate Exercise: Substantial clinical evidence confirms that low- to moderate-intensity physical activity is safe, well-tolerated, and therapeutically beneficial for the vast majority of cancer survivors.
  • Elimination of Barriers: Requiring universal physician clearance creates substantial administrative burdens, leads to lengthy treatment delays, and erects unnecessary barriers to physical activity adoption.
  • Asymptomatic Sedentary Populations: Asymptomatic adults, including sedentary cancer survivors, can safely initiate low- to moderate-intensity exercise without formal medical sign-off.
  • Reliance on Clinical Judgment: Exercise physiologists are urged to employ professional discernment, objective screening algorithms, and validated triage frameworks to determine when specialist medical evaluation is genuinely indicated.

• The Critical Three-Month Treatment Window:

  • Medical clearance is explicitly recommended prior to starting or advancing an exercise regimen for individuals who:
    • Are currently undergoing active cancer treatments (e.g., systemic chemotherapy, biological therapies, radiotherapy, extensive immunotherapy cycles).
    • Are within $3\,\text{months}$ of completing past treatment.
    • Are scheduled to commence treatment within the upcoming $3\,\text{months}$.
  • Physiological Justification for the 3-Month Window:
    • Represents a critical high-risk period characterized by acute treatment toxicities, nadirs in hematological indices, and exercise-related systemic complications.
    • Accounts for residual physiological stress, lingering cellular damage, organ strain, and immunosuppression.
    • Provides an opportunity to identify and track evolving treatment toxicities in real time.
    • Facilitates anticipatory risk mitigation for toxicities secondary to scheduled antineoplastic regimens.
    • Fosters multidisciplinary communication with oncology teams to ascertain critical clinical specifics, such as cumulative anthracycline doses, planned surgeries, or radiation fields intersecting cardiac tissue.

• NCCN Triage Approach to Medical Clearance:

  • The National Comprehensive Cancer Network (NCCN) establishes a clinical triage system matching the client's presentation to specific clearance pathways:
    • No Comorbidities: No medical evaluation or physician clearance needed; client may safely commence exercise.
    • Mild to Moderate Complications: Medical evaluation is recommended. Presentations include stable chemotherapy-induced peripheral neuropathy (CIPN), compromised bone mineral density (osteopenia/osteoporosis), stable lymphoedema, secondary sarcopenia, and manageable post-treatment cancer-related fatigue.
    • Complex Clinical Complications: Medical clearance is mandatory. Presentations include established cardiovascular disease (CVD), recent major thoracic, pulmonary, or abdominal surgical resections, extreme cancer-related fatigue (CRF), motor ataxia, severe nutritional deficiencies, and progressive cancer cachexia.

Risk Stratification and Screening Across the Cancer Continuum

• Pre-Treatment Phase:

  • Risk Level: Moderate.
  • Recommended Screening Strategy:
    • Medical clearance is formally recommended if the client is within $3\,\text{months}$ of their scheduled treatment start date.
    • Graded Exercise Stress Testing (GXST) is generally not required.
    • Standardized pre-exercise screening procedures (e.g., APSS) must be completed.

• Active Treatment Phase:

  • Risk Level: High.
  • Recommended Screening Strategy:
    • Formal medical clearance is highly recommended.
    • GXST is generally not required for low- to moderate-intensity activity.
    • Complete standard pre-exercise screening instruments.
    • Execute individualized, granular body systems screening tailored to specific antineoplastic agents and acute toxicities.

• Post-Treatment: Recovery and Rehabilitation Phase:

  • Risk Level: Moderate to High.
  • Recommended Screening Strategy:
    • Medical clearance is highly recommended, particularly when transitioning from acute hospital care to ambulatory exercise settings.
    • GXST is generally not required in the absence of cardiac red flags.
    • Standard screening (APSS) must be performed.
    • Execute individualized screening focused on residual side effects, deconditioning, and structural deficits.

• Post-Treatment: Disease-Free Survivorship Phase:

  • Risk Level: Moderate.
  • Recommended Screening Strategy:
    • Routine medical clearance and GXST are generally not required.
    • Follow standard adult pre-exercise screening procedures.
    • Implement individualized screening for late-emerging treatment effects, cardiovascular sequelae, secondary primary malignancies, and osteoporosis.

• Palliative Phase (Including Long-Term Stable Advanced Disease):

  • Risk Level: Variable (Moderate to High).
  • Recommended Screening Strategy:
    • Follow standard pre-exercise screening protocols.
    • Medical clearance is highly recommended prior to initiating or adjusting physical activity programs.
    • GXST is generally not required.
    • Conduct comprehensive, personalized evaluations addressing disease progression, metastatic sites, treatment-specific toxicities, and overall symptom burden.

• Clinical Criteria for Pre-Exercise Diagnostic Testing (GXST and Echocardiography):

  • Comprehensive laboratory-based exercise testing is ideal for establishing baseline physiological parameters but is not compulsory for cancer survivors initiating low-intensity aerobic activity (e.g., walking, cycling), progressive resistance training, or range-of-motion (ROM) exercises.
  • Pre-exercise testing protocols for cancer survivors do not differ methodologically from standard population guidelines.
  • Graded Exercise Stress Testing (GXST) or resting/stress transthoracic echocardiography is specifically warranted when individuals present with:
    • Confirmed cardiovascular disease diagnoses or active symptoms (e.g., angina, palpitations, unexplained dyspnoea, presyncope).
    • Known renal pathology or chronic metabolic disease (e.g., poorly controlled type 1 or 2 diabetes mellitus, chronic kidney disease [CKD]).
    • Exposure history to cardiotoxic therapies, including anthracyclines (e.g., doxorubicin, epirubicin), monoclonal antibodies targeting HER2 (e.g., trastuzumab), or radiation fields involving the mediastinum/cardiac silhouette.

Systematic Body Systems-Based Screening and the PRO-CTCAE Library

• Value of the Body Systems Screening Approach:

  • Comprehensive Scope: Prevents the omission of subtle or multi-organ treatment toxicities.
  • Reproducibility: Offers an organized, repeatable clinical framework for baseline assessments and follow-up reviews.
  • Interdisciplinary Integration: Clarifies specific clinical triggers that necessitate referrals to oncologists, cardiologists, dietitians, or physical therapists.
  • Enhanced Clinical Communication: Standardizes health records into logical physiological domains, streamlining multidisciplinary information sharing.
  • Longitudinal Tracking: Creates robust physiological baselines, enabling rapid detection of emerging late-effects or acute functional declines.
  • Patient Education: Promotes health literacy by explaining symptoms through structured bodily systems, empowering clients to self-monitor and report symptoms.

• Procedural Execution of Body Systems Screening:

  • Step 1: Diagnosis and Treatment Appraisal: Verify cancer histological type, anatomical location, tumor stage, past therapies, active regimens, and planned future interventions. Cross-reference these treatments against known toxicity profiles.
  • Step 2: Systematic Domain Review: Conduct targeted questioning, physical observation, and symptom checklists across core physiological domains:
    • Cardiovascular: Chest tightness, angina, palpitations, peripheral dependent oedema, orthostatic or resting blood pressure fluctuations.
    • Musculoskeletal: Cancer-related fatigue, focal muscle weakness, arthralgia, bone pain, structural bone compromise, range-of-motion reductions.
    • Pulmonary: Exertional dyspnoea, persistent non-productive cough, wheezing, reduced functional capacity.
    • Gastrointestinal: Nausea, vomiting, diarrhea, constipation, anorexia, dysgeusia, cachexia.
    • Neurological: Chemotherapy-induced peripheral neuropathy (stocking-glove paresthesia/numbness), balance impairment, motor ataxia, vertigo, neurocognitive alterations ("chemobrain").
    • Immune: Severe myelosuppression, fever, chills, diaphoresis, unhealed lesions, catheter/port site infection.
    • Psychological: Clinical anxiety, depressive episodes, fear of disease recurrence, distress, emotional volatility.
  • Step 3: Clinical Documentation: Quantify symptom frequency, severity, and functional interference. Document domains showing no current signs but carrying future risk.
  • Step 4: Longitudinal Monitoring and Education: Advise clients that treatment toxicities may emerge months or years following therapy completion; institute routine, scheduled re-screening.

• Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE):
  • Developed by the National Cancer Institute (NCI) to capture symptomatic adverse events directly from cancer patients.
  • Symptoms are measured across specific standardized attributes: F = Frequency; S = Severity; I = Interference with daily activities; P = Presence/Absence; A = Amount.
  • Oral Domain: Dry mouth (S), difficulty swallowing (S), mouth/throat sores (SI), cheilosis/cheilitis (cracking at mouth corners) (S), voice quality changes (P), hoarseness (S).
  • Gastrointestinal Domain: Taste changes (S), decreased appetite (SI), nausea (FS), vomiting (FS), heartburn (FS), gas (P), bloating (FS), hiccups (FS), constipation (S), diarrhea (F), abdominal pain (FSI), fecal incontinence (FI).
  • Respiratory Domain: Shortness of breath (SI), cough (SI), wheezing (S).
  • Cardio/Circulatory Domain: Swelling (FSI), heart palpitations (FS).
  • Cutaneous Domain: Rash (P), skin dryness (S), acne (S), hair loss (A), itching (S), hives (P), hand-foot syndrome (S), nail loss (P), nail ridging (P), nail discoloration (P), sensitivity to sunlight (P), bed/pressure sores (P), radiation skin reaction (S), skin darkening (P), stretch marks (P).
  • Neurological Domain: Numbness and tingling (SI), dizziness (SI).
  • Visual/Perceptual Domain: Blurred vision (SI), flashing lights (P), visual floaters (P), watery eyes (SI), ringing in ears (tinnitus) (S).
  • Attention/Memory Domain: Concentration difficulty (SI), memory impairment (SI).
  • Pain Domain: General pain (FSI), headache (FSI), muscle pain (myalgia) (FSI), joint pain (arthralgia) (FSI).
  • Sleep/Wake Domain: Insomnia (SI), fatigue (SI).
  • Mood Domain: Anxious (FSI), discouraged (FSI), sad (FSI).
  • Genitourinary Domain: Irregular periods/vaginal bleeding (P), missed expected menstrual period (P), vaginal discharge (A), vaginal dryness (S), painful urination (dysuria) (S), urinary urgency (FI), urinary frequency (FI), change in urine color (P), urinary incontinence (FI).
  • Sexual Domain: Ability to achieve and maintain an erection (S), ejaculation problems (F), decreased libido (S), delayed orgasm (P), inability to achieve orgasm (anorgasmia) (P), pain with sexual intercourse (dyspareunia) (S).
  • Miscellaneous Domain: Breast swelling/tenderness (S), bruising (P), chills (FS), increased sweating (diaphoresis) (FS), decreased sweating (anhidrosis) (P), hot flashes (FS), epistaxis (nosebleeds) (FS), pain and swelling at injection site (P), unusual body odor (S).

Absolute and Relative Contraindications to Exercise in Cancer Clients

• ACSM General Contraindications to Exercise Testing:

  • Absolute Contraindications (Testing/High-Intensity Exercise Strictly Prohibited):
    • Recent significant change in resting ECG indicating acute ischemia, acute myocardial infarction within $2\,\text{d}$, or other acute cardiac events.
    • Unstable angina pectoris.
    • Uncontrolled symptomatic cardiac dysrhythmias producing hemodynamic instability.
    • Symptomatic severe aortic stenosis.
    • Uncontrolled symptomatic heart failure.
    • Acute pulmonary embolism or pulmonary infarction.
    • Acute myocarditis or pericarditis.
    • Suspected or known aortic dissecting aneurysm.
    • Acute systemic infection accompanied by pyrexia, body aches, or swollen lymph nodes.
  • Relative Contraindications (Testing/Exercise May Proceed if Benefits Outweigh Risks, using Low-Level Endpoints):
    • Left main coronary artery stenosis.
    • Moderate stenotic valvular heart disease.
    • Serum electrolyte abnormalities (e.g., hypokalemia, hypomagnesemia).
    • Severe arterial hypertension at rest (Systolic Blood Pressure $> 200\,\text{mm}\,\text{Hg}$ and/or Diastolic Blood Pressure $> 110\,\text{mm}\,\text{Hg}$).
    • Tachydysrhythmias or bradydysrhythmias.
    • Hypertrophic cardiomyopathy and other mechanical outflow tract obstructions.
    • Neuromotor, musculoskeletal, or rheumatoid disorders exacerbated by exercise.
    • High-degree atrioventricular (AV) blocks.
    • Ventricular aneurysm.
    • Uncontrolled metabolic diseases (e.g., uncontrolled diabetes mellitus, thyrotoxicosis, myxedema).
    • Chronic infectious diseases (e.g., HIV/AIDS).
    • Mental or cognitive impairment leading to an inability to follow instructions or exercise safely.

• Cancer-Specific Absolute Contraindications:

  • Exercise must not be initiated or continued under any circumstances until the acute event is fully resolved and written medical clearance is obtained:
    • Fever or suspected systemic/local infection (body temperature $> 38^\circ\text{C}$, rigors, sweats).
    • Uncontrolled acute pain, intractable nausea, or severe active vomiting.
    • Unstable bone metastases (severe structural lytic lesions at impending risk of pathological fracture).
    • Acute onset of neurological deficits (sudden unilateral weakness, motor ataxia, acute dizziness, sudden mental confusion, slurred speech).
    • Extreme, debilitating cancer-related fatigue or sudden functional decline that impairs fundamental activities of daily living (ADLs).

• Cancer-Specific Relative Contraindications (Mina et al., 2018):

  • Exercise must not commence or progress without obtaining explicit medical clearance from the oncology team. However, unlike absolute contraindications, the underlying clinical condition does not need to be completely resolved prior to initiating safe, modified exercise once clearance is granted:
    • Resting Heart Rate: $\ge 120\,\text{bpm}$.
    • Resting Peripheral Oxygen Saturation: $\text{SpO}_2 \le 88\%$.
    • Circulating Haemoglobin: $\le 80\,\text{g}\,\text{L}^{-1}$.
    • Total White Blood Cell Count (WBC): $\le 2.0 \times 10^9\,\text{L}^{-1}$.
    • Absolute Neutrophil Count (ANC): $\le 1.5 \times 10^9\,\text{L}^{-1}$.
    • Circulating Platelet Count: $< 20 \times 10^9\,\text{L}^{-1}$.
    • Fasting or Random Blood Glucose: $< 5.5\,\text{mmol}\,\text{L}^{-1}$.
    • Sudden, unexplained onset of severe localized pain, rapid joint/limb swelling, or functional dysfunction.
    • Recent surgical intervention (pending tissue healing, suture removal, and surgeon sign-off).
    • Presence of indwelling intravenous lines, vascular access ports, or catheters (e.g., Peripherally Inserted Central Catheters [PICC], port-a-caths, central venous catheters [CVC]), which necessitate movement modifications to avoid displacement, occlusion, or shear stresses.

• Hematological Specifics: Differentiating WBC and ANC:

  • White Blood Cell Count (WBC): Quantifies total circulating leukocytes. Normal differential comprises:
    • Neutrophils: $40\text{--}60\%$
    • Lymphocytes: $20\text{--}40\%$
    • Monocytes: $2\text{--}8\%$
    • Eosinophils: $1\text{--}4\%$
    • Basophils: $0.5\text{--}1\%$
  • Absolute Neutrophil Count (ANC): Directly quantifies circulating mature neutrophils, the primary first-line immune defense against acute bacterial and fungal pathogens.
  • Clinical Dissociation: Although ANC generally declines in parallel with total WBC during post-chemotherapy nadirs, total WBC can remain within normal reference ranges while the client has profound neutropenia ($\text{ANC} \le 1.5 \times 10^9\,\text{L}^{-1}$), placing them at severe risk of opportunistic infections and neutropenic sepsis.

Purpose, Professionalism, and Legal Foundations of the Initial Consultation

• Core Purpose of the Initial Consultation:

  • The initial consultation provides an organized, therapeutic platform to:
    • Build professional rapport, interpersonal connection, and therapeutic alliance.
    • Acquire a comprehensive medical, surgical, and pharmacological profile.
    • Detect latent exercise risks, functional red flags, and pathology-specific contraindications.
    • Determine personalized physical activity, physiological, and psychosocial needs.
    • Establish baseline functional capacity and quantify physical activity habits.
    • Clarify personal motivations, intrinsic drives, and life goals.
    • Identify psychosocial dynamics, emotional distress, social support networks, and environmental barriers.
    • Set collaborative clinical expectations and co-design a personalized exercise management plan.

• Interpersonal Dynamics and Therapeutic Presence:

  • Establishing Trust Early: First impressions dictate therapeutic engagement; clinicians must demonstrate professionalism through attire, vocal cadence, and empathetic posture.
  • Eye Contact: Maintain culturally sensitive, engaged eye contact that communicates respect and undivided attention.
  • Personalization: Address clients by their preferred names and validate their individualized cancer trajectory.
  • Empathy and Active Listening: Validate emotional distress and physiological trauma through active listening, reflective summarization, and uninterrupted patient speech.

• Informed Consent Principles and Legal Requirements:
  • Informed consent is an indispensable ethical, clinical, and legal prerequisite.
  • To satisfy legal standards, clients must clearly understand:
    • The explicit physiological nature, operational protocols, risks, and prospective benefits of exercise physiology interventions.
    • The exact procedures for collecting, securing, storing, and utilizing their private medical records.
  • Core Mandates of the Consent Process:
    • Elucidate the clinical scope and parameters of exercise physiology care.
    • Secure explicit authorization to engage in functional fitness assessments and targeted exercise therapy.
    • Secure consent to archive confidential clinical data.
    • Secure formal authorization to liaise and share clinical metrics with the client's cancer care team (oncologists, surgeons, GPs, specialized nurses).
    • Reinforce the client's unconditional legal right to withdraw consent at any time without compromising ongoing medical care.
  • Documentation Standards:
    • Written General Consent: Must always be obtained in writing prior to initiating clinical care.
    • Specific Procedural Consents: Consent for discrete, high-demand testing protocols, programmatic changes, or specific interdisciplinary data transfers may be provided verbally, but must be documented in the permanent electronic health record.
  • ESSA Standard Consent Disclosures: Formally acknowledges rare but real adverse events, including acute musculoskeletal sprains/strains, severe fatigue, dizziness, nausea, skeletal fractures, intervertebral disc pathology, transient ischemic attacks/strokes, myocardial infarction, acute hypoglycaemic reactions, and exacerbation of pre-existing comorbidities; clarifies that functional outcomes cannot be unconditionally guaranteed; verifies voluntary consent devoid of duress; and specifies operational clinic cancellation fees.

Structured Client Interview and Comprehensive Medical History Taking

• Chronological Flow of the Consultation:

  • Phase 1: Professional Welcome and Orientation
  • Phase 2: Exploration of Primary Reason for Consultation
  • Phase 3: Collection of Demographic and Personal Information
  • Phase 4: Medical History Taking (Cancer Medical History, Other Medical History, Pharmacotherapy Review, Allied Health Network, Lifestyle Habits)
  • Phase 5: Readiness for Exercise Evaluation and Collaborative Goal Setting
  • Phase 6: Objective Clinical Assessments and Physical Testing

• Documenting the Primary Reason for Consultation:

  • Clarify the client's underlying internal motivation for presenting, recognizing that personal drivers frequently diverge from the diagnostic indications stated on physician referral sheets.
  • Identify the chief complaint and explore related physical signs, aggravating postures/movements, and alleviating factors.
  • Assess the direct functional limitations impacting activities of daily living (ADLs), occupation, and recreational interests.
  • Evaluate current self-management strategies, complementary therapies, and pharmaceutical regimens.
  • Review relevant diagnostic indicators, including blood chemistry panels, complete blood counts, and circulating tumor biomarkers.

• Collection of Demographic and Contextual Data:

  • Contact Information: Primary residential address, phone contacts, email.
  • Emergency Contact: Full legal name, relation, and contact numbers of next of kin.
  • Demographic Profile: Chronological age, self-identified gender, educational background.
  • Medical Alerts: Anaphylactic allergies, pharmacological sensitivities, environmental triggers.
  • Communication Profile: Primary language spoken, need for accredited interpreter services.
  • Cultural Identity: Indigenous heritage (Aboriginal and/or Torres Strait Islander status) or distinct cultural requirements.
  • Environmental and Social Context: Living arrangements, home layout, availability of care partners, domestic responsibilities, and access to private or public transit systems.

• Granular Cancer Medical History:

  • Primary Diagnostic Details: Specific anatomical cancer diagnosis, histological subtype, date and diagnostic methodology (biopsy, imaging, screening), and staging (TNM classification, histological grade).
  • Presenting Symptoms: Historical symptomatology that prompted initial clinical investigation.
  • Disease Trajectory: Active macroscopic disease, complete radiological remission, stable non-progressing disease, primary recurrence, or secondary primary malignancy.
  • Multimodal Treatment Chronology:
    • Surgical Interventions: Dates, anatomical margins, lymph node dissections, radical versus breast-conserving procedures, reconstructive surgeries, and internal prosthetic implants.
    • Cytotoxic Chemotherapy: Specific pharmaceutical agents, anthracycline exposures, cycle numbers, delivery routes, and scheduling (neoadjuvant, adjuvant, palliative).
    • Radiotherapy: Total Gray dosage, anatomical target fields (noting proximity to cardiac, pulmonary, or osseous tissue), fractionations, and completion dates.
    • Endocrine Therapies: Aromatase inhibitors (e.g., anastrozole, letrozole), Selective Estrogen Receptor Modulators (SERMs, e.g., tamoxifen), Androgen Deprivation Therapy (ADT, e.g., leuprolide).
    • Targeted Therapies and Immunotherapies: Monoclonal antibodies (e.g., trastuzumab), immune checkpoint inhibitors, tyrosine kinase inhibitors, and associated systemic toxicities.
    • Vascular Access Devices: Historical or present indwelling venous lines, PICC lines, or subcutaneous vascular access ports.
  • Functional and Physiological Sequelae:
    • Musculoskeletal: Joint ROM restrictions, axial/appendicular strength losses, secondary sarcopenia, osteopenia, bone pain.
    • Cardiorespiratory: Exertional dyspnea, resting tachycardia, exercise intolerance, persistent cancer-related fatigue.
    • Functional Status: Disruptions to gait kinematics, balance stability, ADLs, and domestic independence.
    • Body Composition: Sarcopenic obesity, muscle wasting, fluid retention, or clinical lymphoedema.
    • Psychosocial Health: Disrupted sleep architecture, emotional distress, anxiety, depressive symptoms, and diminished quality of life (QoL).

• Non-Cancer Comorbidities and Family History:

  • Given that cancer incidence rises sharply with advancing chronological age, clinicians must anticipate and screen for complex co-existing chronic conditions:
    • Cardiovascular: Hypertension, ischemic heart disease, peripheral vascular disease, chronic arrhythmias.
    • Metabolic and Endocrine: Type 1 and 2 diabetes mellitus, metabolic syndrome, thyroid dysfunction.
    • Neurological: Cerebrovascular accident/stroke, transient ischemic attacks, neurodegenerative conditions.
    • Pulmonary: Chronic Obstructive Pulmonary Disease (COPD), chronic asthma, emphysema.
    • Musculoskeletal and Skeletal: Osteoporosis, osteoarthritis, rheumatoid arthritis.
    • Autoimmune and Immunological: Systemic lupus erythematosus, psoriasis, chronic inflammatory conditions.
    • Neurocognitive and Psychological: Memory consolidation deficits, executive dysfunction, major depressive disorders, generalized anxiety disorders.
  • Family Medical History: Documenting familial patterns of familial breast/ovarian syndromes, colorectal cancers (e.g., Lynch syndrome), premature cardiovascular events, and early-onset metabolic disorders to inform long-term preventative health planning.

• Pharmacotherapy and Supplement Review:

  • Systematic reconciliation of all active medications:
    • Prescription Drugs: Medical indication, daily dosing, schedule/timing relative to exercise bouts, and documented compliance.
    • Exercise Interactions: Identify medications altering hemodynamic responses (e.g., beta-blockers blunting exercise heart rate; ACE inhibitors increasing orthostatic hypotension risks; insulin potentiating exercise-induced hypoglycemia).
    • Over-the-Counter Drugs and Complementary Compounds: Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs), analgesics, vitamins, high-dose antioxidants, and herbal supplements.

• Concurrent Interdisciplinary Healthcare Providers:

  • Identify all health professionals involved in the client's care, such as medical oncologists, surgical oncologists, radiation oncologists, oncology clinical nurse consultants, primary care physicians (GPs), physiotherapists, accredited practicing dietitians, lymphoedema specialists, occupational therapists, and clinical psychologists.
  • Document usage of complementary therapists, such as remedial massage therapists, acupuncturists, and naturopaths, to ensure cohesive multidisciplinary care and avoid contradictory clinical instructions.

Assessment of Lifestyle Behaviours and Contextual Determinants

• Assessment of Core Lifestyle Factors:

  • Tobacco Use: Current smoking frequency, lifetime package-year history, cessation attempts, and current readiness to quit.
  • Nutritional Adequacy: Daily macronutrient and fluid intake, clinical appetite suppression, unintended weight loss, and medically mandated dietary restrictions.
  • Alcohol Intake: Quantity, weekly frequency, binge drinking episodes, and behavioral patterns.
  • Sleep Patterns: Total nocturnal duration, frequent awakenings, nocturnal diaphoresis, insomnia, and waking restorative status.

• Quantifying Physical Activity History:

  • Past exercise patterns strongly predict long-term exercise adherence.
  • Current Baseline Activity: Quantify structured exercise sessions, spontaneous physical activity, and domestic/occupational movement using validated instruments like the International Physical Activity Questionnaire (IPAQ) or the APSS activity matrix.
  • Historical Activity Patterns: Pre-morbid fitness habits, lifetime exercise volume, athletic history, and post-diagnosis movement declines.

• Contextual Facilitators and Barriers to Physical Activity:

  • Exercise Preferences: Individual versus structured group settings, outdoor versus indoor facility environments, favored time of day, and preferred modalities.
  • Equipment and Facility Access: Home exercise equipment, public park access, or local gym memberships.
  • Social Support Structures: Support from domestic partners, family members, exercise companions, or cancer support groups.
  • Oncology-Specific Exercise Barriers: Significant cancer-related fatigue, persistent pain syndromes, fear of exacerbating disease or precipitating lymphoedema, financial constraints, lack of exercise knowledge, dependent care duties, and geographic or transportation isolation.

Exercise Motivation, Transtheoretical Model, and Stage-Matched Interventions

• Transtheoretical Model (TTM) Stages of Change:
  • Assessing motivational readiness enables clinicians to tailor behavioral interventions to the client's current stage of psychological readiness.
  • Definition of Regular Physical Activity: Accumulating a minimum of $30\,\text{minutes}$ of moderate-intensity physical activity per day, on at least $5\,\text{days}\,\text{week}^{-1}$ (totaling $\ge 150\,\text{minutes}\,\text{week}^{-1}$).

• TTM Algorithmic Assessment Tool:

  • Step 1: Clinician asks: "Are you regularly physically active?"
    • If NO: Proceed to Step 2A.
    • If YES: Proceed to Step 2B.
  • Step 2A (Inactive Path): Clinician asks: "Do you intend to become regularly active in the next $30\,\text{days}$?"
    • If YES: The client is in the Preparation Stage.
    • If NO: Clinician asks: "Do you intend to become regularly active in the next $6\,\text{months}$?"
      • If YES: The client is in the Contemplation Stage.
      • If NO: The client is in the Precontemplation Stage.
  • Step 2B (Active Path): Clinician asks: "Have you been regularly physically active for more than $6\,\text{months}$?"
    • If NO: The client is in the Action Stage (regularly active, but for $< 6\,\text{months}$).
    • If YES: The client is in the Maintenance Stage (regularly active for $\ge 6\,\text{months}$).

• Stage-Matched Goals and Action Strategies:

  • Precontemplation:
    • Goal: Prompt the client to start considering physical activity.
    • Strategies: Provide educational literature, reputable videos, and survivor testimonials explaining exercise safety in cancer; collaboratively compile a list of meaningful physical activity benefits and assess their personal relevance.
  • Contemplation:
    • Goal: Motivate the client to start being physically active.
    • Strategies: Identify perceived barriers (e.g., fatigue, lack of time) and develop targeted solutions (e.g., scheduling a $10\,\text{minute}$ walk during lunch); establish a small, achievable starting goal (e.g., $5\,\text{minutes}\,\text{day}^{-1}$ of light walking) and commit to it; refer to an Accredited Exercise Physiologist (AEP) if clinical supervision is needed.
  • Preparation:
    • Goal: Encourage the client to establish a regular physical activity routine.
    • Strategies: Introduce pedometers, accelerometers, or activity logs to track progress toward goals; establish positive self-rewards for meeting activity targets; place environmental visual prompts around the home (e.g., walking shoes by the front door); refer to an AEP for expert exercise prescription and structured supervision.
  • Action:
    • Goal: Support the client in maintaining their new physical activity habit over time.
    • Strategies: Proactively identify emerging obstacles (e.g., treatment schedules, inclement weather) and establish concrete contingency plans; establish intermediate functional goals for upcoming events (e.g., community fun walk, $5\,\text{km}$ charity event); encourage continued participation in supervised exercise sessions if oversight is needed.
  • Maintenance:
    • Goal: Prevent relapses during setbacks and maintain enjoyment of physical activity.
    • Strategies: Develop action plans to resume exercise following disruptions (e.g., acute surgeries, systemic illness, seasonal breaks); enhance enjoyment by introducing novel modalities, listening to podcasts/music, exercising with peers, or utilizing outdoor trails; encourage the client to mentor other cancer survivors initiating exercise; provide ongoing access to supervised clinical exercise services as needed.

SMART Goal Setting Across Intervention Timeframes

• The SMART Goal Framework:

  • Specific: Explicitly identify the target movement, modality, or physiological metric.
  • Measurable: Establish concrete, quantifiable criteria to track objective progress.
  • Achievable: Ensure goals are realistic relative to current functional capacity, treatment toxicities, and available resources.
  • Relevant: Directly connect the goal to the client's functional priorities, personal values, and oncology recovery milestones.
  • Time-Bound: Define a clear, bounded timeframe for re-assessment and achievement.

• Chronological Goal Structure in Oncology Rehabilitation:

  • Short-Term Goals ($1\,\text{week}$ Duration):
    • Focus on establishing immediate behavioral changes, removing domestic friction, and building initial self-efficacy.
    • Clinical Example: Place walking shoes by the front entrance on $3\,\text{mornings}$ this week.
  • Medium-Term Goals ($2\text{--}4\,\text{weeks}$ Duration):
    • Focus on habit formation, routine stabilization, and progressive tolerance to exercise volume.
    • Clinical Example: Complete a continuous $20\,\text{minute}$ outdoor walk at moderate intensity on $3\,\text{mornings}\,\text{week}^{-1}$ for the next $2\,\text{weeks}$.
  • Long-Term Goals ($6\text{--}12+\,\text{weeks}$ Duration):
    • Target clinically meaningful improvements in functional independence, physiological capacity, and body composition.
    • Clinical Example: Increase estimated cardiorespiratory aerobic capacity by $10\%$ within a structured $10\,\text{week}$ progressive exercise program.

Multidimensional Client Assessments and Objective Outcome Measures

• Core Principles of Client Assessment:

  • Goal-Oriented and Problem-Focused: Tests must benchmark the client's primary complaints and align with their SMART functional goals (e.g., addressing cancer-related fatigue, reversing sarcopenia, restoring joint mobility, or improving QoL).
  • Multidimensional Design: Assessments must capture both subjective patient-reported symptom burden and objective physiological performance.
  • Evidence-Informed Selection: Employ validated, reliable assessment batteries with proven safety and utility in oncology cohorts.
  • Dynamic Monitoring and Shared Decision-Making: Assessment data should guide exercise progression, refine exercise dosage, foster collaborative clinical relationships, and generate objective reports for the broader oncology multidisciplinary team.

• Taxonomy of Objective and Subjective Clinical Outcome Measures:

  • Aerobic and Cardiorespiratory Fitness:
    • Submaximal treadmill or cycle ergometer protocols.
    • Modified Bruce Treadmill Protocol.
    • YMCA Submaximal Step Test.
    • Astrand-Rhyming Cycle Ergometer Test.
    • Six-Minute Walk Test ($6\text{MWT}$) or Twelve-Minute Walk Test ($12\text{MWT}$).
    • $400\,\text{m}$ Walk Test ($400\text{m WT}$).
  • Muscular Strength:
    • One-Repetition Maximum ($1\text{RM}$) or multiple-RM testing (e.g., $3\text{RM}$, $5\text{RM}$, $10\text{RM}$).
    • Isometric handgrip dynamometry.
    • Indirect strength assessments, including the $30\,\text{second}$ Sit-to-Stand ($30\text{s STS}$) and the Five-Times Sit-to-Stand ($5\text{x STS}$).
    • Rating of Perceived Exertion (RPE) recorded after a defined repetition load.
  • Muscular Endurance:
    • Push-up test (standard or modified knee-support).
    • Prone plank endurance test.
    • McGill trunk and lumbar stability battery (isometric trunk flexion, trunk extension, and lateral side-bridge tests).
    • Maximum repetitions completed to muscular failure at a standardized percentage of body mass or submaximal load.
    • Trunk curl or traditional sit-up assessments.
  • Functional Mobility and Dynamic Balance:
    • Timed Up and Go (TUG) test.
    • $10\,\text{m}$ Walk Test (evaluating preferred and fast gait speeds).
    • $30\text{s STS}$ and $5\text{x STS}$.
    • $4\text{-Stage Balance Test}$ (progressing through parallel, semi-tandem, tandem, and single-leg balance stances).
    • Functional Reach Test.
    • Berg Balance Scale.
  • Flexibility and Range of Motion (ROM):
    • Sit-and-reach flexibility test.
    • Goniometric measurements of active and passive joint angles (particularly across surgical scars, radiation fibrosis sites, and axillary/pectoral fields).
    • Indirect flexibility indicators (e.g., fingers-to-floor test).
  • Physiological and Morphological Indices:
    • Resting Heart Rate (RHR) and Resting Blood Pressure (RBP).
    • Dual-Energy X-Ray Absorptiometry (DXA), bioelectrical impedance analysis (BIA), or anthropometric circumference testing to track total lean tissue mass, fat mass, visceral adipose tissue, and regional fluid distribution/lymphoedema.
  • Patient-Reported Outcome Measures (PROMs):
    • EORTC QLQ-C30: European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire, assessing general cancer symptom scales and functional domains.
    • FACT-G: Functional Assessment of Cancer Therapy – General, evaluating physical, social/family, emotional, and functional well-being.
    • DASS / DASS-21: Depression, Anxiety and Stress Scale, quantifying emotional states.
    • SF-36: 36-Item Short Form Survey, quantifying broad mental and physical health constructs.
    • POMS: Profile of Mood States, assessing transient mood states, tension, depression, anger, vigor, fatigue, and confusion.